Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lakefront Biotherapeutics N.V. (LKFT)
Mechelen, BE
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Based on only 1 article — low confidence
- Acquisition of Own Shares GlobeNewsWire
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14% | +3.21% | +5.13% | -8.86% | -8.80% | -11.62% | +0.35% | -30.58% | -63.43% | -45.22% | +88.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 3 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
298.80M
est.
|
1.11B
est: 321.73M (+245.7%)
|
27.77M
6.40M – 42.49M
-91.4% YoY
|
37.85M
8.73M – 57.92M
+36.3% YoY
|
28.37M
6.54M – 43.40M
-25.1% YoY
|
39.70M
9.15M – 60.74M
+40.0% YoY
|
55.90M
12.88M – 85.52M
+40.8% YoY
|
| EBITDA |
96.43M
est.
|
358.96M
est: 103.84M (+245.7%)
|
8.96M
2.07M – 13.71M
-91.4% YoY
|
12.22M
2.82M – 18.69M
+36.3% YoY
|
9.16M
2.11M – 14.01M
-25.1% YoY
|
12.81M
2.95M – 19.60M
+40.0% YoY
|
18.04M
4.16M – 27.60M
+40.8% YoY
|
| EBIT |
81.42M
est.
|
303.09M
est: 87.67M (+245.7%)
|
7.57M
1.74M – 11.58M
-91.4% YoY
|
10.32M
2.38M – 15.78M
+36.3% YoY
|
7.73M
1.78M – 11.83M
-25.1% YoY
|
10.82M
2.49M – 16.55M
+40.0% YoY
|
15.23M
3.51M – 23.30M
+40.8% YoY
|
| Net Income |
-34.76M
est.
|
320.88M
est: -422.14M (+176.0%)
|
-214.98M
-491.87M – -61.57M
+49.1% YoY
|
-187.12M
-294.54M – -117.12M
+13.0% YoY
|
-250.83M
-423.63M – 88.3K
-34.0% YoY
|
-183.33M
-309.64M – 64.5K
+26.9% YoY
|
-173.59M
-293.18M – 61.1K
+5.3% YoY
|
| SGA |
30.08M
est.
|
111.96M
est: 32.39M (+245.7%)
|
2.80M
644.4K – 4.28M
-91.4% YoY
|
3.81M
878.3K – 5.83M
+36.3% YoY
|
2.86M
658.2K – 4.37M
-25.1% YoY
|
4.00M
921.2K – 6.11M
+40.0% YoY
|
5.63M
1.30M – 8.61M
+40.8% YoY
|
| EPS |
-0.53
est.
|
4.87
est: -6.41 (+176.0%)
|
-3.26
-7.46 – -0.93
+49.1% YoY
|
-2.84
-4.47 – -1.78
+13.0% YoY
|
-3.81
-6.43 – 0.00
-34.0% YoY
|
-2.78
-4.70 – 0.00
+26.9% YoY
|
-2.63
-4.45 – 0.00
+5.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-11 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-10 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-09 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-08 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-05 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-04 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-03 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-02 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-06-01 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-18 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-15 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 1/5 | 4/5 | 5/5 | 4/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 1.00% | 2.14M | 0.50% |
| 2 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.53% | 117.1K | 0.20% |
| 3 | iShares Biotechnology ETF IBB | 0.10% | 9.02M | 0.44% |
| 4 | Avantis International Small Cap Equity ETF AVDS | 0.07% | 219.8K | 0.30% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.06% | 3.23M | 0.06% |
| 6 | ActivePassive International Equity ETF APIE | 0.05% | 502.6K | 0.45% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 4.99M | 0.06% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 144.7K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 23.4K | 0.19% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 22.9K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Henry Gosebruch | CEO & Executive Director | 1M | male |
| Annelies Missotten | Executive Officer | — | female |
| Ellen Van Der Aar | Head of Development | — | female |
| Fred W. Blakeslee | Executive VP & General Counsel | — | male |
| Glenn Schulman D. | Head of Investor Relations | — | — |
| Jeevan Shetty | Head of Clinical Development Oncology | — | — |
| John W. Mellors | Head of Cell & Antibody Therapy Discovery | — | — |
| Marieke Vermeersch | Head of Corporate Communication | — | — |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy | — | — |
| Aaron L. Cox | Chief Financial Officer | — | male |
| Tania Philipp | Chief Human Resources Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LKFT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
